论文部分内容阅读
目的评价地特胰岛素(Det)联合瑞格列奈治疗新诊断的2型糖尿病(T2DM)患者的有效性和安全性。方法将56例住院治疗的新诊断T2DM患者,随机分为Det联合瑞格列奈组和预混人胰岛素(诺和灵30R)组进行治疗,观察治疗前后的FBG、2hBG、HbA1 c、低血糖发生率、体重增加情况和依从性。结果治疗12周后,两组患者的FBG、2hBG、HbA1c均较基线显著降低。Det联合瑞格列奈组和预混人胰岛素组,低血糖发生率分别为0.080、0.150,体重增加发生率分别为0.029、0.035,治疗依从率分别为0.893、0.679。结论 Det联合瑞格列奈治疗,可显著降低新诊断的住院T2DM患者的血糖水平,并且具有较好的安全性和治疗依从性。
Objective To evaluate the efficacy and safety of detemir (Det) combined with repaglinide in newly diagnosed type 2 diabetes mellitus (T2DM). Methods 56 newly diagnosed T2DM patients hospitalized were randomly divided into Det combined with repaglinide group and pre-mixed insulin (Novolin 30R) group for treatment, before and after treatment of FBG, 2hBG, HbA1c, hypoglycemia Incidence, weight gain and compliance. Results After 12 weeks of treatment, FBG, 2hBG and HbA1c in both groups were significantly lower than baseline. Det combined with repaglinide group and pre-mixed insulin group, the incidence of hypoglycemia were 0.080,0.150, the incidence of weight gain were 0.029,0.035, the treatment compliance rates were 0.893,0.679. Conclusion Det combined with repaglinide can significantly reduce the blood glucose level of newly diagnosed inpatients with T2DM and has good safety and treatment compliance.